HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Granberry, M. C. Articles by Franks, A. M. Search for Related Content PubMed PubMed Citation Articles by Granberry, M. C. Articles by Franks, A. M.

MARK C. GRANBERRY, PHARM.D., is Associate Professor and Chair, Department of Pharmacy Practice, University of the Incarnate Word School of Pharmacy, San Antonio, TX. JASON B. HAWKINS, PHARM.D., is Clinical Pharmacist, Central Arkansas Veterans Healthcare System, Little Rock, and Clinical Assistant Professor, College of Pharmacy, University of Arkansas for Medical Sciences (UAMS), Little Rock. AMY M. FRANKS, PHARM.D., is Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, UAMS.

Address correspondence to Dr. Franks at the Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, 4301 West Markham Street, #522, Little Rock, AR 72205 (afranks{at}uams.edu).

Purpose. A review of the significant findings related to the use of the thiazolidinediones (TZDs) in the treatment of patients with type 2 diabetes mellitus and heart failure was conducted. Summary. TZDs are antihyperglycemic medications that increase insulin sensitivity and improve the underlying defect of insulin resistance and type 2 diabetes mellitus, and they have the potential to slow or decrease the cardiovascular damage that results from these conditions. TZDs are also implicated in weight gain; however, this is accompanied by an improvement in insulin sensitivity and, therefore, its clinical significance is unclear. Edema has been well characterized in patients treated with TZDs. Edema is more common in patients treated with a TZD in combination with insulin and higher doses of TZDs. Because of the potential for fluid retention and worsening edema, clinical studies have excluded patients with New York Heart Association (NYHA) functional class III or IV heart failure. In patients at risk for heart failure or those who have NYHA functional class I or II symptoms, initiation of therapy should be at the lower dose for TZDs with close monitoring of weight gain, edema, and other signs of worsening heart failure. Conclusion. Current data suggest that TZDs may be used cautiously in patients with type 2 diabetes mellitus who are at risk for heart failure or who have NYHA functional class I or II heart failure. Patients with NYHA functional class III or IV heart failure should not receive TZDs. Index terms: Diabetes mellitus; Dosage; Drug interactions; Heart failure; Insulin; Insulins; Mechanism of action; Thiazolidinediones; Toxicity

 

This article has been cited by other articles:

				I-M. Liu, T.-F. Tzeng, and S.-S. Liou A Chinese Herbal Decoction, Dang Gui Bu Xue Tang, Prepared from Radix Astragali and Radix Angelicae sinensis, Ameliorates Insulin Resistance Induced by A High-Fructose Diet in Rats Evid. Based Complement. Altern. Med., February 20, 2009; (2009) nep004v1. [Abstract] [Full Text] [PDF]

				J. S. Stroup Thiazolidinedione-induced edema in patients with heart failure Am. J. Health Syst. Pharm., December 1, 2007; 64(23): 2426 - 2430. [Full Text] [PDF]